Hemab Therapeutics has made a strong impression at the ISTH 2026 Congress in Paris by presenting groundbreaking clinical data for its HMB-002 treatment targeting Von Willebrand disease (VWD) and announcing the development of HMB-003 for heavy menstrual bleeding.
Innovative Approaches to Blood Coagulation Disorders
"Millions of people living with bleeding disorders including VWD and heavy menstrual bleeding have no reliable way to prevent excessive bleeds," said Benny Sørensen, MD, PhD, CEO of Hemab.
- HMB-002 achieves significant increases in Von Willebrand Factor and Factor VIII.
- HMB-003 targets heavy menstrual bleeding with a non-hormonal approach.
The data for HMB-002 demonstrated a dose-dependent increase in Von Willebrand Factor (VWF) and Factor VIII (FVIII), with a notable 2.4-fold peak increase. This treatment aims to normalize thrombin generation and activated partial thromboplastin time (APTT), allowing for potential monthly subcutaneous dosing.
HMB-003, on the other hand, is designed as a direct plasmin inhibitor, offering a new, non-hormonal method to manage heavy menstrual bleeding, a condition that affects one in three women and significantly impacts their quality of life.
Clinical observations from the HMB-002 trials indicated that 8 out of 9 evaluable patients experienced no treated bleeds within 28 days of receiving the treatment, highlighting its effectiveness.
Historically, treatment options for VWD have focused on managing symptoms rather than addressing the underlying causes. Hemab's innovative approach could pave the way for a paradigm shift in how these conditions are treated.
Hemab Therapeutics aims to fill critical gaps in the treatment of bleeding disorders, with its pipeline also including therapies for other high-unmet-need conditions. As VWD remains the most common inherited bleeding disorder, the success of these new treatments could have a substantial impact on patient care.